scholarly journals Social, demographic, health care and co-morbidity predictors of tuberculosis mortality in Amazonas, Brazil: a multiple cause of death approach

2019 ◽  
Author(s):  
Vanderson de Souza Sampaio ◽  
Leila Cristina Ferreira da Silva ◽  
Daniel Barros de Castro ◽  
Patrícia Carvalho da Silva Balieiro ◽  
Ana Alzira Cabrinha ◽  
...  

AbstractOBJECTIVESTo estimate TB mortality rates, describe multiple causes in death certificates in which TB was reported and identify predictors of TB reporting in death certificates in the State of Amazonas, Brazil, based on a multiple cause of death approach.METHODSDeath records of residents in AM within 2006-2014 were classified based on tuberculosis reporting in the death certificate as tuberculosis not reported (TBNoR), reported as the underlying cause of death (TBUC) and as an associate cause of death (TBAC). Age standardized annual mortality rates for TBUC, TBAC and with TB reported (TBUC plus TBAC) were estimated for the State of Amazonas, using the direct standardization method and WHO 2000-2025 standard population. Mortality odds ratios (OR) of reporting TBUC and TBAC were estimated using multinomial logistic regression.RESULTSAge standardized annual TBUC and TBAC mortality rates ranged, between 5.9-7.8/105 and 2.7-4.0/105, respectively. TBUC was associated with residence in the State capital (OR=0.66), female sex (OR=0.87), education level (OR=0.67 and 0.50 for 8 to 11 and 12 or more school years), non-white race/skin colour (OR=1.38) and occurrence of death in the State capital (OR=1.69). TBAC was related to time (OR=1.21 and 1.22 for years 2009-11 and 2012-14), age (OR=36.1 and 16.5 for ages 15-39 and 40-64 years) and when death occurred in the State capital (OR=5.8).CONCLUSIONTBUC was predominantly associated with indicators of unfavorable socioeconomic conditions and health care access constraints, whereas TBAC was mainly related to ages typical of high HIV disease incidence.Conflicts of interestNone.FundingFundação de Amparo à Pesquisa do Estado do Amazonas - FAPEAM

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
A B Guerra ◽  
L M Guerra ◽  
L F Probst ◽  
B V Castro Gondinho ◽  
G M Bovi Ambrosano ◽  
...  

Abstract Background The state of São Paulo recorded a significant reduction in infant mortality, but the desired reduction in maternal mortality was not achieved. Knowledge of the factors with impact on these indicators would be of help in formulating public policies. The aims of this study were to evaluate the relations between socioeconomic and demographic factors, health care model and both infant mortality and maternal mortality in the state of São Paulo, Brazil. Methods In this ecological study, data from national official open sources were used. Analyzed were 645 municipalities in the state of São Paulo, Brazil. For each municipality, the infant mortality and maternal mortality rates were calculated for every 1000 live births, 2013. The association between these rates, socioeconomic variables, demographic models and the primary care organization model in the municipality were verified. We used the zero-inflated negative binomial model. Gross analysis was performed and then multiple regression models were estimated. For associations, we adopted “p” at 5%. Results The increase in the HDI of the city and proportion of Family Health Care Strategy implemented were significantly associated with the reduction in both infant mortality (neonatal + post-neonatal) and maternal mortality rates. In turn, the increase in birth and caesarean delivery rates were associated with the increase in infant and maternal mortality rates. Conclusions It was concluded that the Family Health Care Strategy model that contributed to the reduction in infant (neonatal + post-neonatal) and maternal mortality rates, and so did actors such as HDI and cesarean section. Thus, public health managers should prefer this model. Key messages Implementation of public policies with specific focus on attenuating these factors and making it possible to optimize resources, and not interrupting the FHS. Knowledge of the factors with impact on these indicators would be of help in formulating public policies.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2117-2117
Author(s):  
Courtney Fitzhugh ◽  
Darlene Allen ◽  
Wynona Coles ◽  
Cassie Seamon ◽  
Xiongce Zhao ◽  
...  

Abstract Abstract 2117 Sickle cell disease (SCD) causes significant morbidity and early mortality. The largest study to date reported in 1994 a median survival of 42 years for men and 48 years for women with homozygous SCD1. One third died during a vaso-occlusive crisis, and 18% died of acute organ failure. Circumstances of death were unknown in 18% of patients. With improved patient care in the current era including hydroxyurea (HU) therapy, we sought to identify age and causes of death and associated clinical variables in adults with SCD at a single referral institution. We first reviewed death certificates and assigned one or more causes of death based on all listed data. We studied autopsy reports and medical records and communicated with medical providers when available to identify further causes of death. We then performed a cross sectional analysis of clinical features obtained at initial enrollment and compared those variables in patients who are now living versus deceased using univariate t-test or Chi-squared analysis in order to determine which factors may be associated with death. 528 patients with SCD evaluated at the National Institutes of Health between 2001 and 2010 were included. Out of 511 patients with known genotypes, 391 patients had homozygous SCD. 85 of 528 (16%) died at a median age of 43 years for men and 44 years for women. Death certificates were available for 55 (65%) patients. SCD and infection were the most common listed cause of death (12% each), followed by pulmonary hypertension and/or cor pulmonale (9%), cardiac etiology (8%), narcotic toxicity (7%), and other (31%). Cause of death was unavailable in 18 (21%) cases. Deceased patients were significantly older at the time of first enrollment compared to living patients (41.5 vs. 34.1 years, p<0.0001). There was no significant gender difference between groups. There was also no significant difference in the reported use of HU or fetal hemoglobin levels. Enrollment laboratories suggesting renal insufficiency in deceased patients included a higher creatinine, phosphorus, and uric acid (p<0.02). Hepatic dysfunction was also more prevalent in the deceased group as evidenced by significantly higher direct bilirubin and alkaline phosphatase and lower albumin (p<0.005). There was no difference in alanine transaminase levels. Lactate dehydrogenase (LDH) was significantly higher in deceased patients (p=0.01). As there was no significant difference in hemoglobin, indirect bilirubin, or absolute reticulocyte counts between groups, higher LDH in deceased patients suggests a non-erythrocytic source. Ferritin levels and percent saturation of transferrin were significantly higher and transferrin significantly lower (p<0.004) suggesting more iron overload in deceased patients. Lastly, brain natriuretic peptide levels (reported only in patients with creatinine <1mg/dL) and tricuspid regurgitant velocity were also significantly increased (p<0.0001), suggesting higher prevalence of cardiopulmonary disease in deceased patients. In summary, the most common listed cause of death was nonspecific and unrevealing, reported as SCD. Surprisingly, another common cause of death was infection. This may be due to the combination of poor organ function reserve and functional asplenia. Deceased subjects were older and more likely to have organ impairment at initial evaluation. These data suggest that while contemporary management of patients with SCD may decrease acute manifestations, end organ damage still occurs. Lastly, markers of organ function should be closely monitored as patients increase in age, and organ-specific and definitive disease-specific therapy should be considered before irreversible organ damage ensues. 1 Platt OS et al. NEJM, 1994. 330(23): 1639–1644. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 3747-3747
Author(s):  
Michael Dennis ◽  
Nigel H. Russell ◽  
Nicki Panoskaltsis ◽  
Claire Jane Hemmaway ◽  
Donald Milligan ◽  
...  

Abstract The older patient with AML represents an important subgroup who are often not considered fit for traditional “3+7” type chemotherapy. Although demethylation agents and low dose Ara-c (LDAC) are superior to best supportive care, other options have so far failed to improve survival which is typically 3-4 months. Much of the problem could be attributed to chemoresistance of the leukaemic clone. Vosaroxin is a first in class anti-cancer quinolone which by intercalating into DNA has topoisomerase II inhibitory properties and can by-pass resistance mediated by P-glycoprotein or P53. This results in less free radical production, which has been associated with anthracycline toxicity. In preliminary studies in relapsed/refractory patients >70 yrs, remission rates of up to 30% were observed, with a low 30 day mortality of <10%. In preclinical testing we documented synergy with Ara-C. It was therefore considered to be a candidate treatment in our “Pick a Winner” trial design either alone or combined with LDAC. Two parallel studies. Study 1 (02/2012-11/2013) 104 untreated patients with AML or high risk MDS (>10% marrow blasts) equally randomised between Vosaroxin and LDAC. Study 2 (06/2012-08/2013) 104 patients equally randomised between Vosaroxin + LDAC vs LDAC. Treatment plan was for 4 courses of allocated therapy with the option to extend for patient benefit. Study 1: Median age 75 (60-89); 8/104 had MDS, 31/104 had secondary AML; the risk categories were 3 favourable, 37 intermediate and 64 poor. Study 2 Median age 75(60-91); 12/104 had MDS, 27/104 had secondary AML; 1 fav, 41 int and 62 poor. There were no significant differences between randomised arms. There was no cardiac/renal co-morbidity restriction to entry in either study. The median number of courses delivered (investigational vs LDAC) Study 1(1.0 vs 2.5); Study 2(1.0 vs 2.0). Vosaroxin was 75mg/m2 IV infusion on days 1 and 4. LDAC as 20mg twice a day SC days 1-10. Toxicities NCICTC v.3. RESULTS: Study 1: 28% had a complete marrow response (CR 15%; CRi 13%), with no difference between LDAC (CR 16%; CRi 14%) and Vosaroxin (CR 15%; Cri 11%). The 60 day mortality was greater in the Vosaroxin arm (38% vs 20%; HR 2.16 (1.05-4.43) p=0.04), with increased oral and GI toxicity, more resource use, antibiotics days and hospitalisation. Of those who did not respond, survival on the Vosaroxin arm was worse (1.9 vs 4.9mo: HR 1.68(1.04-2.71), p=0.03). In the responders the OS from response was better on LDAC (17.5 vs 6.9 mo, p=0.04). There was a trend for a better RFS in the LDAC arm (30% vs 8%). Because of the increased early mortality and inferior RFS the OS at 12 mo on vosaroxin was worse than LDAC (12% vs 31%; HR 1.94(1.26-3.00), p=0.003) with a median OS of 3.2 vs 9.0 mo respectively. Cause of death (Vosa vs LDAC: resistant 21 vs 23; infection 10 vs 8; recurrent disease 6 vs 5; cardiac 3 vs 0; pulmonary 1 vs 1; haemorrhage 1 vs 0; renal 0 vs 1; multiple 4 vs 3; other/unknown 2 vs 1). Study 2: 36% response (CR 22%; CRi 14%), no significant difference between LDAC (CR 20%; CRi 14%) and LDAC+ Vosaroxin (CR 25%; CRi 13%). The day 60 mortality was greater on the combo arm (36% vs 18% HR 2.12 (1.01-4.45), p=0.05). Of the non-responders those on the combo arm had worse survival (1.5 vs 4.1 mo; HR 1.92 (1.1-3.31), p=0.02). Survival of responders was not significantly different (median not reached vs 10.1 mo). No relapsed patient survived beyond 9 mo, although survival was better in the LDAC compared to the combo arm (8.8 vs 2.7 mo, p=0.05). The inferior outcome for patients on the combo arm who did not achieve CR or relapsed resulted in non-significantly worse OS (9.6 vs 3.1 mo HR 1.30 (0.81-2.07), p=0.3). Cause of death (Vosa+LDAC vs LDAC: resistant 16 vs 19; infection 9 vs 10; infection+haemorrhage 1 vs 0; recurrent disease 4 vs 4; cardiac 2 vs 0 other cancer 1 vs 0; renal 1 vs 0; other/unk 3 vs 1). In exploratory subgroup analysis we found no evidence of any subgroup that showed a survival benefit. According to the rules of Pick a Winner there had to be evidence of a superior remission rate; while this was passed the increased 60-day mortality and non-significantly worse survival (p=0.10 at time of DMEC meeting) led to a recommendation for closure. Conclusion: In spite of the attributes of Vosaroxin, we failed to find benefit in unselected patients classified as unfit for intensive chemotherapy, either as monotherapy, or in combination with LDAC. Acknowledgments: We are grateful to Sunesis for supporting this Investigator Initiated Study. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 439-439
Author(s):  
Susan Paulukonis ◽  
Todd Griffin ◽  
Mei Zhou ◽  
James R. Eckman ◽  
Robert Hagar ◽  
...  

Abstract On-going public health surveillance efforts in sickle cell disease (SCD) are critical for understanding the course and outcomes of this disease over time. Once nearly universally fatal by adolescence, many patients are living well into adulthood and sometimes into retirement years. Previous SCD mortality estimates have relied on data from death certificates alone or from deaths of patients receiving care in high volume hematology clinics, resulting in gaps in reporting and potentially biased conclusions. The Registry and Surveillance System for Hemoglobinopathies (RuSH) project collected and linked population-based surveillance data on SCD in California and Georgia from a variety of sources for years 2004-2008. These data sources included administrative records, newborn screening reports and health insurance claims as well as case reports of adult and pediatric patients receiving care in the following large specialty treatment centers: Georgia Comprehensive Sickle Cell Center, Georgia Regents University, Georgia Comprehensive Sickle Cell Center at Grady Health Systems and Children's Healthcare of Atlanta in Georgia, and Children's Hospital Los Angeles and UCSF Benioff Children's Hospital Oakland in California. Cases identified from these combined data sources were linked to death certificates in CA and GA for the same years. Among 12,143 identified SCD cases, 640 were linked to death certificates. Combined SCD mortality rates by age group at time of death are compared to combined mortality rates for all African Americans living in CA and GA. (Figure 1). SCD death rates among children up to age 14 and among adults 65 and older were very similar to those of the overall African American population. In contrast, death rates from young adulthood to midlife were substantially higher in the SCD population. Overall, only 55% of death certificates linked to the SCD cases had SCD listed in any of the cause of death fields. Thirty-four percent (CA) and 37% (GA) had SCD as the underlying cause of death. An additional 22% and 20% (CA and GA, respectively) had underlying causes of death that were not unexpected for SCD patients, including related infections such as septicemia, pulmonary/cardiac causes of death, renal failure and stroke. The remaining 44% (CA) and 43% (GA) had underlying causes of death that were either not related to SCD (e.g., malignancies, trauma) or too vague to be associated with SCD (e.g., generalized pulmonary or cardiac causes of death. Figure 2 shows the number of deaths by state, age group at death and whether the underlying cause of death was SCD specific, potentially related to SCD or not clearly related to SCD. While the number of deaths was too small to use for life expectancy calculations, there were more deaths over age 40 than under age 40 during this five year period. This effort represents a novel, population-based approach to examine mortality in SCD patients. These data suggest that the use of death certificates alone to identify deceased cases may not capture all-cause mortality among all SCD patients. Additional years of surveillance are needed to provide better estimates of current life expectancy and the ability to track and monitor changes in mortality over time. On-going surveillance of the SCD population is required to monitor changes in mortality and other outcomes in response to changes in treatments, standards of care and healthcare policy and inform advocacy efforts. This work was supported by the US Centers for Disease Control and Prevention and the National Heart, Lung and Blood Institute, cooperative agreement numbers U50DD000568 and U50DD001008. Figure 1: SCD-Specific & Overall African American Mortality Rates in CA and GA, 2004 – 2008. Figure 1:. SCD-Specific & Overall African American Mortality Rates in CA and GA, 2004 – 2008. Figure 2: Deaths (Count) Among Individuals with SCD in CA and GA, by Age Group and Underlying Cause of Death, 2004-2008 (N=615) Figure 2:. Deaths (Count) Among Individuals with SCD in CA and GA, by Age Group and Underlying Cause of Death, 2004-2008 (N=615) Disclosures No relevant conflicts of interest to declare.


2016 ◽  
Vol 48 (6) ◽  
pp. 1700-1709 ◽  
Author(s):  
Yvan Jamilloux ◽  
Delphine Maucort-Boulch ◽  
Sébastien Kerever ◽  
Mathieu Gerfaud-Valentin ◽  
Christiane Broussolle ◽  
...  

We evaluated mortality rates and underlying causes of death among French decedents with sarcoidosis from 2002 to 2011.We used data from the French Epidemiological Centre for the Medical Causes of Death to 1) calculate sarcoidosis-related mortality rates, 2) examine differences by age and gender, 3) determine underlying and nonunderlying causes of death, 4) compare with the general population (observed/expected ratios), and 5) analyse regional differences.1662 death certificates mentioning sarcoidosis were recorded. The age-standardised mortality rate was 3.6 per million population and significantly increased over the study period. The mean age at death was 70.4 years (versus 76.2 years for the general population). The most common underlying cause of death was sarcoidosis. Sarcoidosis decedents were more likely to be males when aged <65 years. When sarcoidosis was the underlying cause of death, the main other mentions on death certificates were chronic respiratory and cardiovascular diseases. The overall observed/expected ratio was >1 for infectious disease, tuberculosis and chronic respiratory disease, and <1 for neoplasms. We observed a north–south gradient of age-standardised mortality ratio at the country level.Despite the limitation of possibly capturing the more severe cases of sarcoidosis, this study may help define and prioritise preventive interventions.


2020 ◽  
Vol 144 (9) ◽  
pp. 1092-1096
Author(s):  
Alison Krywanczyk ◽  
Elaine Amoresano ◽  
Kanayo Tatsumi ◽  
Sharon Mount

Context.— Despite the importance of accurate death statistics for epidemiologic studies and public health initiatives, there remains a high frequency of errors in death certification. This deficiency can be addressed by the hospital autopsy service. Objectives.— To improve the quality and accuracy of death certificates issued in the hospital and improve resident and clinician education by initiating a death certificate review process, performed by pathology residents while on their hospital autopsy rotation. Design.— A resident reviewed all death certificates issued in the hospital daily through the state electronic death certificate filing system and correlated with the decedent's medical record. When errors were found, the resident filed an amended death certificate with the state. If applicable, the Office of the Medical Examiner was contacted to investigate. The original certifying physician was then contacted via email with an explanation for the amendment. Results.— In 12 months, 590 death certificates were issued by the hospital. Eighty-eight of 590 (15%) were amended. Of those 88 amended, 41 (47%) were missing an underlying cause of death, 7 (8%) had an inaccurate cause of death, 41 (47%) failed to include relevant contributory causes of death, and 17 (19%) had major typographic errors. Of 88, 24 (27%) fell under the Office of the Medical Examiner's jurisdiction and were reported with a subsequent change in the manner of death in 23 of 88 cases (26%). Conclusions.— Death certificate review by the autopsy service improves the accuracy of death certification, impacts resident and clinician education, and serves as quality assurance for both the hospital and the state.


PLoS ONE ◽  
2020 ◽  
Vol 15 (2) ◽  
pp. e0229749
Author(s):  
Vanderson de Souza Sampaio ◽  
Maria Gabriela de Almeida Rodrigues ◽  
Leila Cristina Ferreira da Silva ◽  
Daniel Barros de Castro ◽  
Patrícia Carvalho da Silva Balieiro ◽  
...  

2021 ◽  
Author(s):  
Akash Anand ◽  
Divya Khanna ◽  
Payal Singh ◽  
Anuj Singh ◽  
Abhishek Pandey ◽  
...  

Abstract BackgroundMedical Certification of Cause of Death (MCCD) can provide valuable health status data regarding disease incidence, prevalence and mortality in a community. It can guide local health policy and help in setting priorities. On the contrary, incomplete and inaccurate MCCD data can significantly impair the precision of a national health information database. In the current study, the accuracy of death certificates at two tertiary cancer care hospitals in Northern India, has been evaluated.MethodsThis retrospective study has been conducted at Tata Memorial Centres namely, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Varanasi, India on MCCD over a period of two and a half years. Medical records and death certificates of all the deceased were examined. The demographic characteristics, administrative details, co-morbidities and cause of death from death certificates were collected using an approved standardized form. The accuracy of this information was validated using the medical records. Errors in the death certificates were classified according to Haque’s grading scale.1Results778 deaths occurred during the study period between May 2018 to December 2020, and all certificates were accessed for analysis. Only 30 (4%) certificates were error-free. 591(75.9%) death certificates had an inappropriate immediate cause of death. 231(29.7%) death certificates had incorrectly labelled mode of death, such as cardiopulmonary arrest as the immediate cause of death. 585 (75.2%) death certificates had an incorrect underlying cause of death. Majority of the death certificates were prepared by the post MBBS junior residents and this was significantly associated with higher certification errors.ConclusionA high rate of errors was identified in the death certificates completed at our hospitals. Inaccurate death certificates related to cancers can potentially influence the cancer statistics of the defined region and thereby affect policymaking for cancer prevention and control. There is a pressing need for appropriate intervention/s to resolve this important issue. In an attempt to improve the quality of certification, it is envisaged to conduct training for all consultants and residents in proper death certification.


PLoS ONE ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. e0218359 ◽  
Author(s):  
Vanderson de Souza Sampaio ◽  
Maria Gabriela de Almeida Rodrigues ◽  
Leila Cristina Ferreira da Silva ◽  
Daniel Barros de Castro ◽  
Patrícia Carvalho da Silva Balieiro ◽  
...  

2017 ◽  
Vol 44 (5) ◽  
pp. 571-579 ◽  
Author(s):  
Aliasghar A. Kiadaliri ◽  
Aleksandra Turkiewicz ◽  
Martin Englund

Objective.To assess mortality related to musculoskeletal (MSK) disorders and rheumatoid arthritis (RA), specifically, among adults (aged ≥ 20 yrs) in southern Sweden using the multiple-cause-of-death approach.Methods.All death certificates (DC; n = 201,488) from 1998 to 2014 for adults in the region of Skåne were analyzed when mortality from MSK disorders and RA was listed as the underlying and nonunderlying cause of death (UCD/NUCD). Trends in age-standardized mortality rates (ASMR) were evaluated using joinpoint regression, and associated causes were identified by age- and sex-adjusted observed/expected ratios.Results.MSK (RA) was mentioned on 2.8% (0.8%) of all DC and selected as UCD in 0.6% (0.2%), with higher values among women. Proportion of MSK disorder deaths from all deaths increased from 2.7% in 1998 to 3.1% in 2014, and declined from 0.9% to 0.5% for RA. The mean age at death was higher in DC with mention of MSK/RA than in DC without. The mean ASMR for MSK (RA) was 15.5 (4.3) per 100,000 person-years and declined by 1.1% (3.8%) per year during 1998–2014. When MSK/RA were UCD, pneumonia and heart failure were the main NUCD. When MSK/RA were NUCD, the leading UCD were ischemic heart disease and neoplasms. The greatest observed/expected ratios were seen for infectious diseases (including sepsis) and blood diseases.Conclusion.We observed significant reduction in MSK and RA mortality rates and increase in the mean age at death. Further analyses are required to investigate determinants of these improvements in MSK/RA survival and their potential effect on the Swedish healthcare systems.


Sign in / Sign up

Export Citation Format

Share Document